BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 38256131)

  • 1. Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Endometrial Cancer: A Review on Immunohistochemistry Staining Patterns and Clinical Implications.
    Addante F; d'Amati A; Santoro A; Angelico G; Inzani F; Arciuolo D; Travaglino A; Raffone A; D'Alessandris N; Scaglione G; Valente M; Tinnirello G; Sfregola S; Padial Urtueta B; Piermattei A; Cianfrini F; Mulè A; Bragantini E; Zannoni GF
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mismatch Repair Deficiency in Endometrial Cancer: Immunohistochemistry Staining and Clinical Implications.
    Doghri R; Houcine Y; Boujelbène N; Driss M; Charfi L; Abbes I; Mrad K; Sellami R
    Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):678-682. PubMed ID: 31567138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical guidance for mismatch repair-deficiency testing in endometrial cancer.
    Stelloo E; Jansen AML; Osse EM; Nout RA; Creutzberg CL; Ruano D; Church DN; Morreau H; Smit VTHBM; van Wezel T; Bosse T
    Ann Oncol; 2017 Jan; 28(1):96-102. PubMed ID: 27742654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Accuracy of Immunohistochemistry for Mismatch Repair Proteins as Surrogate of Microsatellite Instability Molecular Testing in Endometrial Cancer.
    Raffone A; Travaglino A; Cerbone M; Gencarelli A; Mollo A; Insabato L; Zullo F
    Pathol Oncol Res; 2020 Jul; 26(3):1417-1427. PubMed ID: 32377987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Methods for Testing Mismatch Repair Status in Endometrial Cancer.
    Mendiola M; Heredia-Soto V; Ruz-Caracuel I; Baillo A; Ramon-Patino JL; Escudero FJ; Miguel M; Pelaez-Garcia A; Hernandez A; Feliu J; Hardisson D; Redondo A
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective study of consistency between immunohistochemistry and polymerase chain reaction of microsatellite instability in endometrial cancer.
    Wang C; Kuang W; Zeng J; Ren Y; Liu Q; Sun H; Feng M; Liang D
    PeerJ; 2023; 11():e15920. PubMed ID: 37663290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker.
    Backes FJ; Haag J; Cosgrove CM; Suarez A; Cohn DE; Goodfellow PJ
    Cancer; 2019 Feb; 125(3):398-405. PubMed ID: 30561762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological features of 50 mismatch repair (MMR)-deficient endometrial carcinomas, tested by immunohistochemistry: A single institutional feasibility study, India.
    Rekhi B; Menon S; Deodhar KK; Ghosh J; Chopra S; Maheshwari A
    Ann Diagn Pathol; 2020 Aug; 47():151558. PubMed ID: 32619922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lynch Syndrome in Thai Endometrial Cancer Patients.
    Manchana T; Ariyasriwatana C; Triratanachat S; Phowthongkum P
    Asian Pac J Cancer Prev; 2021 May; 22(5):1477-1483. PubMed ID: 34048176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma].
    Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR
    Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256
    [No Abstract]   [Full Text] [Related]  

  • 11. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
    Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
    Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Significance of Mismatch Repair Deficiency in Young Patients With Endometrial Cancer.
    Chu MM; Liu SS; Tam KF; Ip PP; Cheung AN; Ngan HY
    Int J Gynecol Pathol; 2015 Sep; 34(5):403-10. PubMed ID: 26262451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
    Jin W; Wang LQ; Liu Y; Liu AJ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
    [No Abstract]   [Full Text] [Related]  

  • 14. Somatic Sequencing and Microsatellite Instability Results From Mismatch Repair-deficient Endometrial Carcinoma Patients Without Lynch Syndrome ("Lynch-like" tumors): Implications for Heritable Cancer Screening, Molecular Prognostication, and Immunotherapeutic Vulnerability.
    Makia NL; Thomas M; Ring KL; Moskaluk CA; Mills AM
    Am J Surg Pathol; 2023 Aug; 47(8):878-888. PubMed ID: 37248962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic Cancers.
    Noh JJ; Kim MK; Choi MC; Lee JW; Park H; Jung SG; Joo WD; Song SH; Lee C
    Cancer Res Treat; 2022 Oct; 54(4):1200-1208. PubMed ID: 34902958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.
    McConechy MK; Talhouk A; Li-Chang HH; Leung S; Huntsman DG; Gilks CB; McAlpine JN
    Gynecol Oncol; 2015 May; 137(2):306-10. PubMed ID: 25636458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers].
    Hu XR; Xu C; Kang Y; Wang T; Zhang Y; Yang XH
    Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):827-833. PubMed ID: 30423605
    [No Abstract]   [Full Text] [Related]  

  • 19. Peritumoral granulomatous reaction in endometrial carcinoma: association with DNA mismatch repair protein deficiency, particularly loss of PMS2 expression.
    Stewart CJR; Pearn A; Pachter N; Tan A
    Histopathology; 2018 Sep; 73(3):428-437. PubMed ID: 29710374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of HNPCC by molecular analysis of colorectal and endometrial tumors.
    Vasen HF; Hendriks Y; de Jong AE; van Puijenbroek M; Tops C; Bröcker-Vriends AH; Wijnen JT; Morreau H
    Dis Markers; 2004; 20(4-5):207-13. PubMed ID: 15528786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.